The Full Wiki

More info on Fosaprepitant

Fosaprepitant: Map

  

Wikipedia article:

Map showing all locations mentioned on Wikipedia article:

{{Drugbox
IUPAC_name = [3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo- 2H-1,2,4-triazol-1-yl]phosphonic acid
image = Fosaprepitant.svg
CAS_number = 172673-20-0
CAS_supplemental = (dimeglumine)
ATC_prefix = A04
ATC_suffix = AD12
PubChem = 219090
DrugBank =
H=22|F=7|N=4|O=6|P=1
molecular_weight = 614.406 g/mol
bioavailability = n/a
protein_bound = >95% (aprepitant)
metabolism = To aprepitant
elimination_half-life = 9 to 13 hours (aprepitant)
excretion =
pregnancy_AU =
pregnancy_US = B
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US = Rx-only
routes_of_administration = Intravenous
licence_EU =Ivemend
licence_US =Fosaprepitant}}

Fosaprepitant (Emend for Injection (USmarker), Ivemend (EU)) is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant.

Fosaprepitant was developed by Merck & Co. and was approved by the United Statesmarker Food and Drug Administration (FDA) on January 25, 2008. and by the European Medicines Agency (EMA) on January 11 of the same year.

See also



References


Embed code:






Got something to say? Make a comment.
Your name
Your email address
Message